Joyce O’Shaughnessy, MD | Authors

January 20, 2023

The panel closes their discussion by musing on the future of HER2 mBC treatments.

January 06, 2023

A discussion on the prevalence and treatment difficulties of leptomeningeal metastases in HER2+ mBC.

January 06, 2023

The panel discusses the systemic therapy options for patients with HER2+ mBC with brain metastases before moving to whole brain radiation therapy.

January 06, 2023

Andrew Brenner, MD, presents the case of a 62-year-old patient with stage II HER2+ mBC presenting with both pulmonary and brain metastases.

January 06, 2023

Joyce O’Shaughnessy, MD, starts a conversation on managing the adverse events of tucatinib therapy in patients with HER2+ mBC with brain metastases.

December 22, 2022

The panel reviews the treatment approaches for HER2+ mBC with active brain metastases and the factors to consider during treatment decision-making.

December 22, 2022

Virginia Kaklamani, MD, presents the case of a 60-year-old patient with stage III HER2+ mBC with brain metastases.

December 15, 2022

Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.

December 15, 2022

Andrew Brenner, MD, explains when physicians should screen patients with HER2+ breast cancer for brain metastases.

December 08, 2022

Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.